CoChat
Sign Up
Cited by 247Iron Metabolism and DisordersHormonal and reproductive studiesErythropoietin and Anemia Treatment

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Testosterone Suppresses Hepcidin in Men: A Potential Mechanism for Testosterone-Induced Erythrocytosis

Open access
Bachman, Eric, Feng, Rui, Travison, Thomas, Li, Michelle, Olbina, Gordana, Ostland, Vaughn, Ulloor, Jagadish, Zhang, Anqi, Basaria, Shehzad, Ganz, Tomas, Westerman, Mark, Bhasin, Shalender·2010·The Journal of Clinical Endocrinology & Metabolism
DOI 10.1210/jc.2010-0864PMC PMC3050108
Open this paper in CoChat — free account

Abstract

CONTEXT: The mechanisms by which testosterone increases hemoglobin and hematocrit are unknown. OBJECTIVE: The aim was to test the hypothesis that testosterone-induced increase in hematocrit is associated with suppression of the iron regulatory peptide hepcidin. PARTICIPANTS: Healthy younger men (ages 19-35 yr; n = 53) and older men (ages 59-75 yr; n = 56) were studied. METHODS: Weekly doses of testosterone enanthate (25, 50, 125, 300, and 600 mg) were administered over 20 wk, whereas endogenous testosterone was suppressed by monthly GnRH agonist administration. Blood and serum parameters from each individual were measured at wk 0, 1, 2, 4, 8, and 20. Longitudinal analyses were performed to examine the relationship between hepcidin, hemoglobin, hematocrit, and testosterone while controlling for potential confounders. RESULTS: High levels of testosterone markedly suppressed serum hepcidin within 1 wk. Hepcidin suppression in response to testosterone administration was dose-dependent in older men and more pronounced than in young men, and this corresponded to a greater rise in hemoglobin in older men. Serum hepcidin levels at 4 and 8 wk were predictive of change in hematocrit from baseline to peak levels. CONCLUSION: Testosterone administration is associated with suppression of serum hepcidin. Greater increases in hematocrit in older men during testosterone therapy are related to greater suppression of hepcidin.

Overview

Integrity signals

Registry

Crossref · 10.1210/jc.2010-0864

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 19 references

Cited by

Sorted by citations

See all 247

Related

Metadata

Authors
Bachman, E., Feng, R., Travison, T., Li, M., Olbina, G., Ostland, V., Ulloor, J., Zhang, A., Basaria, S., Ganz, T., Westerman, M., & Bhasin, S.
Affiliations
  • Boston University (US)
  • University of Pennsylvania (US)
  • Intrinsic LifeSciences (United States) (US)
  • University of California, Los Angeles (US)
Corresponding author
Bachman, Eric
ORCID
Venue
The Journal of Clinical Endocrinology & Metabolism
Publisher
The Endocrine Society
Published
2010-10
Volume
95
Issue
10
Pages
4743-4747
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
DOI
10.1210/jc.2010-0864
PMC
PMC3050108
OpenAlex
W2150542348
Cited by
247
References
19
Citations by year
2026: 18 · 2025: 14 · 2024: 9 · 2023: 16 · 2022: 16 · 2021: 11 · 2020: 23 · 2019: 15 · 2018: 13 · 2017: 18 · 2016: 12 · 2015: 20 · 2014: 15 · 2013: 20 · 2012: 16
FWCI
9.41
Type
journal article
Language
en
Open access
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • School of Medicine, Boston University
  • Evans Medical Foundation
  • National Institutes of Health (5p30ag031679-15)
  • National Institute on Aging (U01AG014369, U01 AG14369, P30-AG031679)
Topics
  • Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
  • Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
Keywords
testosterone, hepcidin, testosterone enanthate, hematocrit, hemoglobin, iron regulation, GnRH agonist suppression, dose-response relationship, age differences, men
MeSH terms
Adult, Aged, Aging, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Humans, Injections, Male, Middle Aged, Polycythemia, Testosterone, Down-Regulation, Leuprolide, Antimicrobial Cationic Peptides, Young Adult, Hepcidins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review